Clinical Research Directory

Inclusion Criteria: * Newly diagnosed AML (WHO 2022 classification or ICC 2022 classification) * Participants must be considered Ineligible for intensive induction defined by the following: 1. Age 75 years or older, or 2. Age 18 to 74 years with at least one of the following comorbidities: i) Severe cardiac disorder (eg, congestive heart failure requiring treatment, ejection fraction ≤50%, or chronic stable angina). ii) Severe pulmonary disorder (eg, DLCO ≤65% or FEV1 ≤65%). iii) Creatinine clearance ≥30 mL/min to \<45 mL/min iv) Moderate hepatic impairment with total bilirubin \>1.5 to ≤3.0 × upper limit of normal (ULN). * Must have achieved CR,CRh, CRi, following induction with maximum 3 cycles of standard IV HMAs and venetoclax. * Able to provide informed consent * Prior and concomitant hydroxyurea is permitted * ECOG performance status 0 to 3 Exclusion Criteria: * Progression or relapse after induction standard HMAs + Venetoclax therapy * Pregnancy or breastfeeding * Uncontrolled infection, active CNS disease, or concurrent malignancy requiring systemic therapy * Inability to take oral medication or presence of malabsorption syndrome or any other uncontrolled gastrointestinal condition * Candidate for intensive chemotherapy * Uncontrolled infection, active CNS disease, or concurrent malignancy requiring systemic therapy * Candidate for stem cell transplant